|
|
|
Volumn 22, Issue 138, 2013, Pages 120-
|
|
Danitumumab adjunctive therapy. No place in either first- or second-line treatment of metastatic colorectal cancer.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
EPIDERMAL GROWTH FACTOR RECEPTOR;
MONOCLONAL ANTIBODY;
PANITUMUMAB;
ARTICLE;
COLORECTAL TUMOR;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
METASTASIS;
PATHOLOGY;
SURVIVAL;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
COLORECTAL NEOPLASMS;
HUMANS;
INFUSIONS, INTRAVENOUS;
NEOPLASM METASTASIS;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
SURVIVAL;
|
|
EID: 84880467238
PISSN: 11677422
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (1)
|
|
References (0)
|